Latest Genentech Inc. Stories
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.
The world's pharmaceutical giants invent and market medicines that save, prolong and vastly improve the quality of our lives. In return, we give them more money than most people can imagine.
WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc.
What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
Swiss pharmaceutical behemoth Roche will have to dig deeper into its pockets if it wants to own all of Genentech Inc., which rejected its $43.7 billion offer.
Biotechnology pioneer Genentech Inc. considered Roche Holding's $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the Swiss pharmaceutical giant should pay considerably more.
Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug (IND) application with the U.S.